This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Welcome to Novo Nordisk Rare Diseases Science Hub

 

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a non-US healthcare professional.

Marijke van
den Berg, MD, PhD
Director of the PedNet Haemophilia Research Foundation, the Netherlands, ,

Marijke van den Berg is the Director of the PedNet Haemophilia Research Foundation and Associate Professor at the Department of Health Sciences and Epidemiology, University Medical Centre of Utrecht, the Netherlands. She is also a clinical expert for the Blood Product Working Party, at the European Medicine Agency. Her expertise in haemophilia is in inhibitor development and prophylaxis. She is the initiator and principal investigator of several multi-centre studies on inhibitors.